{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:10:45Z","timestamp":1793211045876,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04214-x","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T12:05:20Z","timestamp":1744373120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adalimumab combination with corticosteroid therapy for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5563-1465","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-412X","authenticated-orcid":false,"given":"Taoye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3904-6692","authenticated-orcid":false,"given":"Tianhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"4214_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","volume":"163","author":"L Valeyrie-Allanore","year":"2010","unstructured":"Valeyrie-Allanore L et al (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163:847\u2013853. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09863.x","journal-title":"Br J Dermatol"},{"key":"4214_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","volume":"128","author":"CW Wang","year":"2018","unstructured":"Wang CW et al (2018) Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest 128:985\u2013996. https:\/\/doi.org\/10.1172\/JCI93349","journal-title":"J Clin Invest"},{"key":"4214_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4103\/0378-6323.116738","volume":"79","author":"GK Singh","year":"2013","unstructured":"Singh GK, Chatterjee M, Verma R (2013) Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol 79:686\u2013692. https:\/\/doi.org\/10.4103\/0378-6323.116738","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"4214_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","volume":"65","author":"Y Yamane","year":"2016","unstructured":"Yamane Y et al (2016) Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients\u2013Treatment and outcome. Allergol Int 65:74\u201381. https:\/\/doi.org\/10.1016\/j.alit.2015.09.001","journal-title":"Allergol Int"},{"key":"4214_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"M Lerch","year":"2018","unstructured":"Lerch M, Mainetti C, Beretta-Piccoli T, B., Harr T (2018) Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 54:147\u2013176. https:\/\/doi.org\/10.1007\/s12016-017-8654-z","journal-title":"Clin Rev Allergy Immunol"},{"key":"4214_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","volume":"151","author":"PD Andrew Gibson","year":"2023","unstructured":"Andrew Gibson PD, Chelsea N, Campbell, Matthew S, Krantz E, Mukherjee M, Mockenhaupt M, Pirmohamed AM, Palubinsky EJ (2023) Phillips. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J Allergy Clin Immunol 151:289\u2013300","journal-title":"J Allergy Clin Immunol"},{"key":"4214_CR7","doi-asserted-by":"publisher","unstructured":"Bellon T et al (2022) IL-15\/IL-15Ralpha in SJS\/TEN: relevant expression of IL15 and IL15RA in affected skin. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10081868","DOI":"10.3390\/biomedicines10081868"},{"key":"4214_CR8","doi-asserted-by":"crossref","unstructured":"Riichiro Abe TS, Shibaki A, Nakamura H, Watanabe H, and, Shimizu H (2003) Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162","DOI":"10.1016\/S0002-9440(10)64284-8"},{"key":"4214_CR9","doi-asserted-by":"publisher","first-page":"CD013130","DOI":"10.1002\/14651858.CD013130.pub2","volume":"3","author":"A Jacobsen","year":"2022","unstructured":"Jacobsen A et al (2022) Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome. Cochrane Database Syst Rev 3:CD013130. https:\/\/doi.org\/10.1002\/14651858.CD013130.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4214_CR10","doi-asserted-by":"publisher","unstructured":"Tian CC et al (2022) Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 129, 360\u2013365 e361. https:\/\/doi.org\/10.1016\/j.anai.2022.05.009","DOI":"10.1016\/j.anai.2022.05.009"},{"issue":"e1296","key":"4214_CR11","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang J et al (2022) Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: A multicenter observational study. J Allergy Clin Immunol Pract 10(e1296):1295\u20131304. https:\/\/doi.org\/10.1016\/j.jaip.2022.01.038","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4214_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s13555-023-00928-w","volume":"13","author":"J Cao","year":"2023","unstructured":"Cao J, Zhang X, Xing X, Fan J (2023) Biologic TNF-alpha inhibitors for Stevens-Johnson syndrome, toxic epidermal necrolysis, and TEN-SJS overlap: A Study-Level and Patient-Level Meta-Analysis. Dermatol Ther (Heidelb) 13:1305\u20131327. https:\/\/doi.org\/10.1007\/s13555-023-00928-w","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4214_CR13","doi-asserted-by":"publisher","first-page":"e12684","DOI":"10.1111\/dth.12684","volume":"31","author":"N So","year":"2018","unstructured":"So N, Leavitt E, Aleshin M, Worswick S (2018) The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential. Dermatol Ther 31:e12684. https:\/\/doi.org\/10.1111\/dth.12684","journal-title":"Dermatol Ther"},{"key":"4214_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bjd\/ljae321","volume":"192","author":"N Hama","year":"2024","unstructured":"Hama N et al (2024) Recent progress in Stevens-Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment. Br J Dermatol 192:9\u201318. https:\/\/doi.org\/10.1093\/bjd\/ljae321","journal-title":"Br J Dermatol"},{"key":"4214_CR15","doi-asserted-by":"publisher","unstructured":"Olsson-Brown A et al (2023) TNF-alpha\u2013Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens\u2013Johnson Syndrome\/Toxic Epidermal Necrolysis. J Invest Dermatol 143, 1023\u20131030 e1027. https:\/\/doi.org\/10.1016\/j.jid.2022.11.024","DOI":"10.1016\/j.jid.2022.11.024"},{"key":"4214_CR16","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1097\/CM9.0000000000003250","volume":"137","author":"A Hasegawa","year":"2024","unstructured":"Hasegawa A, Abe R (2024) Stevens-Johnson syndrome and toxic epidermal necrolysis: updates in pathophysiology and management. Chin Med J (Engl) 137:2294\u20132307. https:\/\/doi.org\/10.1097\/CM9.0000000000003250","journal-title":"Chin Med J (Engl)"},{"key":"4214_CR17","doi-asserted-by":"publisher","unstructured":"Jang DI et al (2021) The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22052719","DOI":"10.3390\/ijms22052719"},{"key":"4214_CR18","doi-asserted-by":"publisher","first-page":"1210026","DOI":"10.3389\/fmed.2023.1210026","volume":"10","author":"EA Nikitina","year":"2023","unstructured":"Nikitina EA et al (2023) Positive experience with TNF-alpha inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids. Front Med (Lausanne) 10:1210026. https:\/\/doi.org\/10.3389\/fmed.2023.1210026","journal-title":"Front Med (Lausanne)"},{"key":"4214_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","volume":"12","author":"G Doherty","year":"2018","unstructured":"Doherty G et al (2018) European Crohn\u2019s and colitis organisation topical review on treatment withdrawal [\u2018Exit Strategies\u2019] in Inflammatory Bowel Disease. J Crohns Colitis 12:17\u201331. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx101","journal-title":"J Crohns Colitis"},{"key":"4214_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2017.11.005","volume":"17","author":"A Rubbert-Roth","year":"2018","unstructured":"Rubbert-Roth A et al (2018) TNF inhibitors in rheumatoid arthritis and spondyloarthritis: are they the same? Autoimmun Rev 17:24\u201328. https:\/\/doi.org\/10.1016\/j.autrev.2017.11.005","journal-title":"Autoimmun Rev"},{"key":"4214_CR21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jaad.2022.10.035","volume":"88","author":"YT Hung","year":"2023","unstructured":"Hung YT et al (2023) Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study. J Am Acad Dermatol 88:792\u2013801. https:\/\/doi.org\/10.1016\/j.jaad.2022.10.035","journal-title":"J Am Acad Dermatol"},{"key":"4214_CR22","doi-asserted-by":"publisher","first-page":"917782","DOI":"10.3389\/fimmu.2022.917782","volume":"13","author":"YT Hung","year":"2022","unstructured":"Hung YT et al (2022) Diagnostic and therapeutic dilemma in Stevens-Johnson syndrome-like acute graft-versus-host disease after liver transplantation: A case report. Front Immunol 13:917782. https:\/\/doi.org\/10.3389\/fimmu.2022.917782","journal-title":"Front Immunol"},{"key":"4214_CR23","doi-asserted-by":"publisher","unstructured":"Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T, Transmembrane (2010) TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49:1215\u20131228. https:\/\/doi.org\/10.1093\/rheumatology\/keq031","DOI":"10.1093\/rheumatology\/keq031"},{"key":"4214_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaad.2023.02.058","volume":"89","author":"T Gong","year":"2023","unstructured":"Gong T et al (2023) APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome\/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts. J Am Acad Dermatol 89:45\u201352. https:\/\/doi.org\/10.1016\/j.jaad.2023.02.058","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04214-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T12:05:23Z","timestamp":1744373123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04214-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4214"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04214-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"694"}}